Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target raised by analysts at Canaccord Genuity Group Inc. from $29.00 to $32.00. They now have a "buy" rating on the stock.
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $17.00. They now have an "outperform" rating on the stock.
Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target lowered by analysts at HC Wainwright from $15.00 to $14.00. They now have a "buy" rating on the stock.
Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results